Absci Corporation Common Stock Morgan Stanley 24th Annual Global Healthcare Conference

Yeah, thanks for having us.

Yeah, obviously, there has been a lot of activity in China, and I think it is about how you utilize China. We obviously have an AI platform, and we look at China and just how we scale our infrastructure. Not necessarily going in and buying assets there, but working with China to be able to rapidly test these hypotheses, get to yes/no answers on new targets, and even looking at how we could potentially utilize them on the clinical development side. I think that, yeah it has been very interesting to see all the activity going on, but we definitely see it as a net positive for the overall space.

Yeah, I think we are most focused on FDA. We are in the middle of our phase I/II trial for pattern hair loss. We are about to initiate a phase II trial in endometriosis. So we are following all of that policy activity. As Sean mentioned, we have a strategy to leverage execution in China, not just pre-clinical execution, but to do proof of concept work in China and phase II development going forward. So we are following all the developments in Congress and policy-wise from the administration, but we do think there is a significant opportunity there to reduce cost, increase speed, and really leverage Chinese execution.

Yeah. So far the trial is going very well. We are very happy with the progress, and we are going to be announcing the phase II efficacy data in December of this year. The recruitment has been going extremely well, and safety profile really good as well, and we are really excited to be announcing this data in December.

Well, first off, I would say we are very pleased with what we are seeing on the half-life. It looks to us like it is going to be either 2 or 3 injections over 6 months, so once every 2 months or once every 3 months. That, at least from our consumer research, is a game changer for the market because the convenience paired with the durability of the effect based on the mechanism, I think would be a completely new premium category of therapy for pattern hair loss and resonates extremely well with customers. When we talk to consumers, we have commissioned a large survey, as you know. They are very dissatisfied with standard of care. A profile that allows for a very simple injection that infrequently with durable effect is very exciting for that population.